NovellusDx is wrapping its transformation into a cancer therapeutics biotech with a new name and new CEO: Fore Biotherapeutics and Usama Malik.
Today Novellus, Ltd., a clinical-stage biotechnology company focused on precision oncology, and Tempus, a leader in artificial intelligence and precision medicine, announced their collaboration to accelerate patient enrollment for Novellus’ next generation BRAF inhibitor program.
JERUSALEM--(BUSINESS WIRE)--Novellus, Ltd., a clinical-stage biotechnology company focused on precision oncology announced today that it has raised $57 million in a Series C financing round. The round was led by Pontifax, and joined by OrbiMed Advisors, HBM Healthcare Investments, Wellington Management, Cormorant Asset Management, Novartis Venture Fund (NVF), SR One, as well as existing investors.
BERKELEY, Calif. & JERUSALEM--(BUSINESS WIRE)--Novellus, a precision-oncology drug development company, announced today that it has entered into an exclusive worldwide license agreement with Plexxikon, a member of the Daiichi Sankyo Group, for PLX8394, its clinical-stage oncology drug candidate which targets the BRAF protein. PLX8394 is currently completing a Phase 1/2 trial in patients with advanced, unresectable solid tumors.
Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.
Market Place
Share Share
Share Share
